<DOC>
	<DOCNO>NCT02878863</DOCNO>
	<brief_summary>An open-label , prospective , randomize pilot study evaluate efficacy , safety tolerability paeoniflorin , treatment autoimmune hepatitis ( AIH ) mild necroinflammatory activity liver biopsy .</brief_summary>
	<brief_title>Paeoniflorin Combination Hepatoprotective Drugs Versus Hepatoprotective Drugs Only Auto-immune Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Peoniflorin</mesh_term>
	<criteria>Patients age 2070 year ; Diagnosed AIH primary biliary cirrhosisautoimmune hepatitis overlap syndrome base liver biopsy result without indication immunosuppressive therapy ; High level alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ( 13 X ULN ) ; High level IgG ( 11.5 X ULN ) ; Liver biopsy show mild lymphocytic piecemeal necrosis ( interface hepatitis ) ; Agreed participate trial , assign informed consent . The presence hepatitis A , B , C , D , E virus infection ; Patients presence liver cirrhosis portal hypertension ; Patients presence fulminant liver failure ; Primary sclerosing cholangitis , nonalcoholic steatohepatitis , drug induce liver disease Wilson disease confirm liver biopsy ; Pregnant breed woman ; Severe disorder vital organ , severe heart failure , cancer ; Parenteral administration blood blood product within 6 month screen ; Recent treatment drug know liver toxicity ; Taken part clinic trial within 6 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>